PLOTS: Percutaneous Localization: Open-label Registry of Thoracic Surgery

Sponsor
Veran Medical Technologies (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04066699
Collaborator
(none)
100
5
29.7
20
0.7

Study Details

Study Description

Brief Summary

The objectives of this study are to evaluate intraoperative percutaneous lung lesion marking assisted by electromagnetic guided percutaneous navigation and related tools.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.

Detailed Description

The Intraoperative, Percutaneous Localization of Peripheral Pulmonary Nodules for Resection:

a Prospective, Open-Label, Multi-Center Registry Study of Thoracic Surgery Outcomes (PLOTS) registry is aimed at developing a high quality set of data regarding intraoperative percutaneous localization of peripheral pulmonary nodules (PPNs), and then identifying and promulgating efficient, evidence-based best practices for this technique. The resection procedure itself is standard of care and follows the investigator's standard protocol.

Successful localization of PPNs is a challenge involving multiple factors, beginning with the subjects' health, lung function and also factors specific to the nodule including location within the lung, size, distance from the lung surface, whether solid or ground glass and proximity to a fissure. Hard to see or palpate nodules are currently localized with dye and/or hook wires or fiducials, either endoscopically or percutaneously. Successful, large, prospective studies have not been reported using modern electro-magnetic navigation (EMN)-guided percutaneous intraoperative localization, and different techniques (dye vs. fiducial vs. hook wire etc.) have not been broadly evaluated. It is for these reasons that the different localization techniques used with EMN-guided percutaneous localization will be collected for patients having a suspicious nodule and who undergo percutaneous intra-operative localization and immediate resection.

This registry aims to record the localization techniques used by thoracic surgeons and IP/surgical teams to identify PPNs using the SPiN Thoracic Navigation System™ in the hands of trained physicians. The objectives of this study will be to accomplish the primary and secondary objectives listed below, and to observe localization in a real world context of pulmonary resection.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Intraoperative, Percutaneous Localization of Peripheral Pulmonary Nodules for Resection: a Prospective, Open-Label, Multi-Center Registry Study of Thoracic Surgery Outcomes.
Actual Study Start Date :
Oct 10, 2019
Anticipated Primary Completion Date :
Feb 1, 2022
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Localization

Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).

Procedure: Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.
Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
Other Names:
  • SPiN Thoracic Navigation System™
  • Veran System
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of successful percutaneous localization and removal of PPN. [Duration of procedure.]

      Successful percutaneous localization of PPN defined as the percentage of subjects in whom the nodule is successfully localized and removed in the first resected specimen.

    2. Collect safety data for localization procedure. [Duration of procedure.]

    Secondary Outcome Measures

    1. Report localization method and technique. [Duration of procedure.]

      Details regarding the localization technique will be collected, including the materials used. If dye (methylene blue, ICG etc.) is used the volume will be collected. Other materials include microcoils, hook wires, etc..

    2. Collect data on intraoperative percutaneous localization time and duration of total surgical procedure. [Duration of procedure.]

      The time of the localization procedure will be recorded. The length of the entire surgical procedure will also be recorded.

    3. Record nodule characteristics, including location in the lobe, distance from pleura, distance from surface of skin to target, morphological appearance, solid vs. ground glass etc. [Duration of procedure.]

    4. Record weight of excised tissue and margin. [Duration of procedure.]

    5. Report type of surgical resection performed and the resection technique used. [Duration of procedure.]

      The surgical resection may include segmentectomy or wedge using the VATS, RATS, or thoracotomy techniques.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subject's physician and/or thoracic surgeon have deemed/has deemed that the surgical removal of the PPN is appropriate.

    • A clinical decision has been made to use the SPiN Thoracic Navigation System™.

    • Subject is at least 18 years of age at time of study entry.

    • Subject is able to read, understand, and voluntarily sign the IRB-approved informed consent document prior to the performance of any study-specific procedures. IRB- approved translation may be used if indicated. Reasonable accommodation of visually impaired subjects will be allowed.

    • Subject is able to tolerate general anesthesia.

    • Subject has a target nodule between 0.4 cm and 3.2 cm in greatest dimension;

    • The target nodule is in a location that is accessible for percutaneous localization in the judgement of the surgeon.

    Exclusion Criteria:
    • Subjects with any other concomitant treatment or medical condition that, in the opinion of the clinician, would render peripheral nodule resection more hazardous than beneficial.

    • Subject is pregnant.

    • Pulmonary nodule is greater than 3.2 cm.

    • Subjects with significant coagulopathy having INR > 2.0 or PTT > 2x normal.

    • Subject is unable to tolerate general anesthesia.

    • Obese subject, impacting percutaneous access (BMI > 50).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kaiser Permanente Lone Tree Colorado United States 80124
    2 Northern Light Eastern Maine Medical Center Bangor Maine United States 04401
    3 Vassar Brothers Medical Center Poughkeepsie New York United States 12601
    4 University of North Carolina at Chapel Hill Chapel Hill North Carolina United States 27599
    5 Houston Methodist Hospital Houston Texas United States 77030

    Sponsors and Collaborators

    • Veran Medical Technologies

    Investigators

    • Principal Investigator: Faiz Bhora, MD, Vassar Brothers Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Veran Medical Technologies
    ClinicalTrials.gov Identifier:
    NCT04066699
    Other Study ID Numbers:
    • VMT-01-003
    First Posted:
    Aug 26, 2019
    Last Update Posted:
    Mar 30, 2021
    Last Verified:
    Mar 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Veran Medical Technologies
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 30, 2021